수의 정밀의료 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 동물별, 치료 영역별, 고객별, 지역별 및 부문별 예측(2026-2033년)

Veterinary Precision Medicine Market Summary

The global veterinary precision medicine market size was estimated at USD 558.9 million in 2025 and is projected to reach USD 1,509.5 million by 2033, growing at a CAGR of 13.5% from 2026 to 2033. The market is growing due to factors such as rising companion animal cancer prevalence, pet humanization boosting treatment investment, AI/ML advancing bioinformatics capabilities, and comparative oncology attracting institutional investment.

The global veterinary precision medicine industry encompasses genomic profiling, molecular diagnostics, precision therapy guidance, and bioinformatics services delivered across companion and production animals, spanning oncology, infectious diseases, immunology, and other therapeutic areas. Commercial service adoption is currently primarily in canine oncology, with expanding applications in feline and other species. The integration of artificial intelligence and machine learning into bioinformatics platforms has significantly elevated the clinical utility of veterinary precision medicine services. Computational models are now capable of converting complex multi-omics and live-cell datasets into individualized, actionable treatment guidance; a capability that was not achievable through conventional genomic analysis alone.

For instance, ImpriMed's platform represents the most commercially validated application of this shift. Its Drug Response Predictions service uses AI models trained on extensive, clinically proven data sources to generate personalized treatment predictions for canine cancer patients, analyzing the efficacy of up to 13 commonly prescribed blood cancer drugs on patients' living cells, with results delivered within 6 to 7 days. Dogs with relapsed B-cell lymphoma treated under ImpriMed's AI-guided predictions recorded a median survival time of 160 to 187 days, as published in Frontiers in Oncology, and 95% of surveyed veterinary oncologists reported satisfaction with the service. To date, ImpriMed's tests have been applied to over 3,700 canine and feline patients over five years, with over 10,000 individual samples analyzed. Furthermore, AI applications are expanding beyond drug response prediction into imaging diagnostics, where machine learning algorithms are being trained to detect tumor-associated abnormalities in radiographic and histopathological data. This broadening of AI utility across the diagnostic and bioinformatics service stack positions the technology as a structural market driver rather than a niche capability.

The translational value of companion animal cancer models is accelerating institutional and commercial investment in veterinary precision medicine infrastructure. Naturally occurring cancers in companion animals share key biological and molecular characteristics with human malignancies, with cross-species insights already informing advances such as limb-sparing surgical techniques derived from canine osteosarcoma research and improved understanding of hormonal influences in human breast cancer through feline mammary tumor studies. A study published in February 2026, conducted across institutions including the Wellcome Sanger Institute, the University of Guelph, and the University of Bern, mapped the oncogenome of the domestic cat across nearly 500 tumor samples sourced from five countries. The study was funded by the EveryCat Health Foundation, CVS Group, Wellcome, the Natural Sciences and Engineering Research Council of Canada, and the Swiss National Science Foundation. This scale of multi-national, multi-funder investment signals a structural shift in how comparative oncology is being prioritized at the institutional level.

In addition, expanding comparative oncology research through broad, multicenter veterinary clinical trials is identified as essential for bridging gaps between preclinical findings and clinical practice, with collaborative networks spanning academic institutions, veterinary practices, industry partners, and regulatory bodies forming translational research frameworks. This institutional convergence is directly expanding the demand and funding base for veterinary precision medicine services.

Global Veterinary Precision Medicine Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the veterinary precision medicine market report based on type, animal, therapeutic area, customer, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Genomic Profiling & Sequencing
• Diagnostic & Pathology
• Precision Therapy & Treatment
• Bioinformatics & Data Analytics
• Animal Outlook (Revenue, USD Million, 2021 - 2033)
• Dogs
• Cats
• Other Animals
• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Infectious Diseases
• Immunology & Autoimmune Disorders
• Musculoskeletal Disorders
• Other Therapeutic Areas
• Customer Outlook (Revenue, USD Million, 2021 - 2033)
• Veterinary Hospitals & Clinics
• Veterinary Academic & Research Institutions
• Veterinary Diagnostic Laboratories
• Other Customers
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Oman
  • Qatar

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Animal
  • 1.2.3. Therapeutic Area
  • 1.2.4. Customers
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information/Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Model 1: Commodity Flow Analysis
  • 1.7.2. Model 2: Bottom-Up Analysis
  • 1.7.3. Model 3: Volume-Pricing Analysis
• 1.8. List of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Ancillary/Related Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Companion Animal Cancer Prevalence
    • 3.2.1.2. Pet Humanization Boosting Treatment Investment
    • 3.2.1.3. AI/ML Advancing Bioinformatics Capabilities
    • 3.2.1.4. Comparative Oncology Attracting Institutional Investment
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Costs Limiting Clinical Adoption
    • 3.2.2.2. Limited Validated Multi-Species Assays
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. Pricing Model Analysis
• 3.4. User Perspective Analysis
• 3.5. Case Study Analysis
• 3.6. Market Analysis Tools
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTEL by SWOT Analysis

Chapter 4. Veterinary Precision Medicine Market: By Type Estimates & Trend Analysis

• 4.1. Veterinary Precision Medicine Market, By Type: Segment Dashboard
• 4.2. Veterinary Precision Medicine Market, By Type: Movement Analysis
• 4.3. Veterinary Precision Medicine Market Estimates & Forecasts, by Type, 2021 to 2033 (USD Million)
• 4.4. Genomic Profiling & Sequencing
  • 4.4.1. Genomic Profiling & Sequencing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Diagnostic & Pathology
  • 4.5.1. Diagnostic & Pathology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Precision Therapy & Treatment
  • 4.6.1. Precision Therapy & Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Bioinformatics & Data Analytics
  • 4.7.1. Bioinformatics & Data Analytics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Veterinary Precision Medicine Market: By Animal Estimates & Trend Analysis

• 5.1. Veterinary Precision Medicine Market, By Animal: Segment Dashboard
• 5.2. Veterinary Precision Medicine Market, By Animal Movement Analysis
• 5.3. Veterinary Precision Medicine Market Estimates & Forecasts, by Animal, 2021 to 2033 (USD Million)
• 5.4. Dogs
  • 5.4.1. Dogs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Cats
  • 5.5.1. Cats Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Other Animals
  • 5.6.1. Other Animals Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Veterinary Precision Medicine Market: By Therapeutic Area Estimates & Trend Analysis

• 6.1. Veterinary Precision Medicine Market, By Therapeutic Area: Segment Dashboard
• 6.2. Veterinary Precision Medicine Market, By Therapeutic Area Movement Analysis
• 6.3. Veterinary Precision Medicine Market Estimates & Forecasts, by Therapeutic Area, 2021 to 2033 (USD Million)
• 6.4. Oncology
  • 6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Infectious Diseases
  • 6.5.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Immunology & Autoimmune Disorders
  • 6.6.1. Immunology & Autoimmune Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Musculoskeletal Disorders
  • 6.7.1. Musculoskeletal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Other Therapeutic Areas
  • 6.8.1. Other Therapeutic Areas Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Veterinary Precision Medicine Market: By Customer Estimates & Trend Analysis

• 7.1. Veterinary Precision Medicine Market, By Customer: Segment Dashboard
• 7.2. Veterinary Precision Medicine Market, By Customer Movement Analysis
• 7.3. Veterinary Precision Medicine Market Estimates & Forecasts, by Customer, 2021 to 2033 (USD Million)
• 7.4. Veterinary Hospitals & Clinics
  • 7.4.1. Veterinary Hospitals & Clinics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Veterinary Academic & Research Institutions
  • 7.5.1. Veterinary Academic & Research Institutions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Veterinary Diagnostic Laboratories
  • 7.6.1. Veterinary Diagnostic Laboratories Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Other Customers
  • 7.7.1. Other Customers Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Veterinary Precision Medicine Market: By Regional Estimates & Trend Analysis

• 8.1. Region Market Dashboard
• 8.2. Region Market Share Analysis, 2025 & 2033
• 8.3. North America
  • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Australia
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. South Korea
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. Saudi Arabia
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.6. Qatar
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.7. Oman
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. Zoetis
    • 9.3.1.1. Participant's Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Product/Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Idexx Laboratories
    • 9.3.2.1. Participant's Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Product/Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. ImpriMed
    • 9.3.3.1. Participant's Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Product/Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. FidoCure (One Health Company)
    • 9.3.4.1. Participant's Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Product/Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Anivive Lifesciences (Vidium Animal Health)
    • 9.3.5.1. Participant's Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Product/Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. VetOmics Animal Health
    • 9.3.6.1. Participant's Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Product/Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. LEAH Labs
    • 9.3.7.1. Participant's Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Product/Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Elias Animal Health
    • 9.3.8.1. Participant's Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Product/Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. testblu diagnostics GmbH
    • 9.3.9.1. Participant's Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Product/Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. PetDx
    • 9.3.10.1. Participant's Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Product/Service Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. Torigen, Inc
    • 9.3.11.1. Participant's Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Product/Service Benchmarking
    • 9.3.11.4. Strategic Initiatives
  • 9.3.12. Oxford BioDynamics
    • 9.3.12.1. Participant's Overview
    • 9.3.12.2. Financial Performance
    • 9.3.12.3. Product/Service Benchmarking
    • 9.3.12.4. Strategic Initiatives